Materia Licenses Metathesis Catalyst Platform To Aileron Therapeutics

PASADENA, Calif.--(BUSINESS WIRE)--Materia, Inc., a catalyst technology company, announced today the licensing of its metathesis platform to Aileron Therapeutics, an emerging biopharmaceutical company, for use in the discovery and development of peptide therapeutics directed at intracellular protein-protein interaction targets. As consideration for the license, Materia will receive license fees, milestone payments, and royalties.

Back to news